Part I Overview We are a clinical-stage biotechnology company focused primarily on developing novel pharmaceuticals to treat cardiometabolic diseases. We have two programs focused primarily on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus( T2DM). Agonism of GPR119 in the gut promotes the rele...
Q2 FY2026 — expected 2026-08-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001104659-26-034911 | EDGAR | 85K words |
| 2025-03-20 | 2024-12-31 | 0001558370-25-003386 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0001558370-24-004246 | EDGAR | — |
| 2023-03-30 | 2022-12-31 | 0001558370-23-005127 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0001558370-22-004958 | EDGAR | — |
| 2021-04-15 | 2020-12-31 | 0001558370-21-004356 | EDGAR | — |
| 2020-03-30 | 2019-12-31 | 0001558370-20-003385 | EDGAR | — |
| 2019-03-18 | 2018-12-31 | 0001558370-19-002192 | EDGAR | — |
| 2018-03-20 | 2017-12-31 | 0001558370-18-002275 | EDGAR | — |
| 2017-03-21 | 2016-12-31 | 0001558370-17-001962 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001104659-25-107726 | EDGAR | 17K words |
| 2025-08-07 | 2025-06-30 | 0001558370-25-010759 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0001558370-25-007749 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001558370-24-014863 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001558370-24-012272 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0001558370-24-007479 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001558370-23-018842 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001558370-23-014299 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001558370-23-009606 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001558370-22-017864 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001558370-22-013500 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001558370-22-008767 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-26 | 0001104659-26-035238 | EDGAR | 5K words |
| 2026-03-26 | 0001104659-26-034907 | EDGAR | — |
| 2026-03-18 | 0001104659-26-029912 | EDGAR | — |
| 2026-01-27 | 0001104659-26-006976 | EDGAR | — |
| 2026-01-16 | 0001104659-26-004532 | EDGAR | — |
| 2026-01-05 | 0001104659-26-000736 | EDGAR | — |
| 2026-01-05 | 0001104659-26-000432 | EDGAR | — |
| 2025-12-19 | 0001104659-25-123099 | EDGAR | — |
| 2025-12-02 | 0001104659-25-117540 | EDGAR | — |
| 2025-11-26 | 0001104659-25-116456 | EDGAR | — |
251 total filings indexed. 219 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001638287 |
| Ticker | MTVA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.metaviatx.com |
| Listed | 2016-08-04 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report